GlassScriptPhysician profile
Natalia Anchipolovsky
NPI 1982725024
$39,517.45
in general payments reported to CMS, 2019-2025
44 companies · $1,832 in 2025
The $1,832 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $11K · 2021: $5,740 · 2022: $6,154 · 2023: $2,188 · 2024: $1,214 · 2025: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,068 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $950 · Education: $147 · Long Term Medical Supply Or Device Loan: $69.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,067.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $950.00 |
| Education | $146.60 |
| Long Term Medical Supply Or Device Loan | $69.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $31,895.06 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $1,482.42 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,018.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $701.45 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Corcept Therapeutics | $599.04 | 2019-2025 | Korlym |
| Abbvie INC. | $438.31 | 2019-2025 | Synthroid, Viberzi, Linzess |
| Sanofi-Aventis U.S. LLC | $407.16 | 2019-2025 | |
| Medtronic, INC. | $325.76 | 2022-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $224.60 | 2022-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $194.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.71 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $176.20 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $157.15 | 2021-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $145.33 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $145.19 | 2019-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Anchipolovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.